475 related articles for article (PubMed ID: 25653541)
1. Triple-negative breast cancer: new perspectives for targeted therapies.
Tomao F; Papa A; Zaccarelli E; Rossi L; Caruso D; Minozzi M; Vici P; Frati L; Tomao S
Onco Targets Ther; 2015; 8():177-93. PubMed ID: 25653541
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
3. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
4. Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Simbault L; Abadie J; Loussouarn D; Campone M; Nguyen F
Tumour Biol; 2020 Jan; 42(1):1010428319901052. PubMed ID: 31959092
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
Bosch A; Eroles P; Zaragoza R; Viña JR; Lluch A
Cancer Treat Rev; 2010 May; 36(3):206-15. PubMed ID: 20060649
[TBL] [Abstract][Full Text] [Related]
6. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.
Gazinska P; Grigoriadis A; Brown JP; Millis RR; Mera A; Gillett CE; Holmberg LH; Tutt AN; Pinder SE
Mod Pathol; 2013 Jul; 26(7):955-66. PubMed ID: 23392436
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancer: an unmet medical need.
Hudis CA; Gianni L
Oncologist; 2011; 16 Suppl 1():1-11. PubMed ID: 21278435
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
10. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
11. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
Mehlich D; Marusiak AA
Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
[TBL] [Abstract][Full Text] [Related]
12. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.
Prado-Vázquez G; Gámez-Pozo A; Trilla-Fuertes L; Arevalillo JM; Zapater-Moros A; Ferrer-Gómez M; Díaz-Almirón M; López-Vacas R; Navarro H; Maín P; Feliú J; Zamora P; Espinosa E; Fresno Vara JÁ
Sci Rep; 2019 Feb; 9(1):1538. PubMed ID: 30733547
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
[TBL] [Abstract][Full Text] [Related]
14. Expression of Basal-like Biomarkers in Triple Negative Invasive Breast Carcinoma in Puerto Rico.
Agosto-Arroyo E; Climent C; Vélez R; Nazario CM; Díaz MV
P R Health Sci J; 2015 Jun; 34(2):89-92. PubMed ID: 26061059
[TBL] [Abstract][Full Text] [Related]
15. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
[TBL] [Abstract][Full Text] [Related]
16. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
17. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
18. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
Izadi P; Mehrdad N; Foruzandeh F; Reza NM
Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
Li J; Liu X; Tong Z
Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
